Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 216-221

  Takagi, Shunsuke ^a,c   Balu, Darrick T ^b,c   Coyle, Joseph T ^b,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

D serine; MK801; Schizophrenia; Serine racemase; Tropomyosin receptor kinase B (trkB)

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; DIZOCILPINE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; ISOMERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE B; SERINE RACEMASE; UNCLASSIFIED DRUG; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; AMINO ACID RECEPTOR BLOCKING AGENT; CYTOSKELETON PROTEIN; DIZOCILPINE MALEATE; GLYCOGEN SYNTHASE KINASE 3; NERVE PROTEIN;

ADULT; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; JUVENILE ANIMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; MALE; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RACEMASES AND EPIMERASES; RECEPTOR, TRKB; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84923254821     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.12.034     Document Type: Article

References (46)

1. Adell A., Jimenez-Sanchez L., Lopez-Gil X., Romon T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr. Bull. 2012, 38(1):9-14.
2. Balu, Coyle J.T. Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Res. 2011, 1392:1-7.
3. Balu D.T., Coyle J.T. Chronic d-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem. Int. 2014, 75:76-78.
4. Balu D.T., Basu A.C., Corradi J.P., Cacace A.M., Coyle J.T. The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol. Dis. 2012, 45(2):671-682.
5. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., Bolshakov V.Y., Coyle J.T. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(26):E2400-E2409.
6. Basu A.C., Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., Jiang Z.I., Benneyworth M.A., Froimowitz M.P., Lange N., Snyder S.H., Bergeron R., Coyle J.T. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 2009, 14(7):719-727.
7. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90(1-3):41-51.
8. Boulay D., Ho-Van S., Bergis O., Avenet P., Griebel G. Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?. Behav. Pharmacol. 2013, (in press).
9. Coyle J.T., Balu D., Benneyworth M., Basu A., Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin. Neurosci. 2010, 12(3):359-382.
10. Daya R.P., Bhandari J.K., Hui P.A., Tian Y., Farncombe T., Mishra R.K. Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats. Neuropharmacology 2014, 77:325-333.
11. DeVito L.M., Balu D.T., Kanter B.R., Lykken C., Basu A.C., Coyle J.T., Eichenbaum H. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav. 2011, 10(2):210-222.
12. Eyjolfsson E.M., Brenner E., Kondziella D., Sonnewald U. Repeated injection of MK801: an animal model of schizophrenia?. Neurochem. Int. 2006, 48(6-7):541-546.
13. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., Georgieva L., Rees E., Palta P., Ruderfer D.M., Carrera N., Humphreys I., Johnson J.S., Roussos P., Barker D.D., Banks E., Milanova V., Grant S.G., Hannon E., Rose S.A., Chambert K., Mahajan M., Scolnick E.M., Moran J.L., Kirov G., Palotie A., McCarroll S.A., Holmans P., Sklar P., Owen M.J., Purcell S.M., O'Donovan M.C. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506(7487):179-184.
14. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):572-576.
15. Hawken E.R., Delva N.J., Beninger R.J. Increased drinking following social isolation rearing: implications for polydipsia associated with schizophrenia. PLoS ONE 2013, 8(2):e56105.
16. Henson M.A., Roberts A.C., Perez-Otano I., Philpot B.D. Influence of the NR3A subunit on NMDA receptor functions. Prog. Neurobiol. 2010, 91:23-37.
17. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 1992, 89(1-2):1-10.
18. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69(8):776-786.
19. Itil T., Keskiner A., Kiremitci N., Holden J.M. Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 1967, 12(2):209-212.
20. Javitt D.C. Sensory processing in schizophrenia: neither simple nor intact. Schizophr. Bull. 2009, 35(6):1059-1064.
21. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
22. Khella R., Short J.L., Malone D.T. CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice. Psychopharmacology 2014, 231(16):3071-3087.
23. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., Grozeva D., Fjodorova M., Wollerton R., Rees E., Nikolov I., van de Lagemaat L.N., Bayes A., Fernandez E., Olason P.I., Bottcher Y., Komiyama N.H., Collins M.O., Choudhary J., Stefansson K., Stefansson H., Grant S.G., Purcell S., Sklar P., O'Donovan M.C., Owen M.J. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2012, 17(2):142-153.
24. Korb E., Finkbeiner S. Arc in synaptic plasticity: from gene to behavior. Trends Neurosci. 2011, 34(11):591-598.
25. Kornhuber J., Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 1997, 41(2):135-144.
26. Lopez-Gil X., Babot Z., Amargos-Bosch M., Sunol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32(10):2087-2097.
27. Lui S., Deng W., Huang X., Jiang L., Ma X., Chen H., Zhang T., Li X., Li D., Zou L., Tang H., Zhou X.J., Mechelli A., Collier D.A., Sweeney J.A., Li T., Gong Q. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. Am. J. Psychiatry 2009, 166(2):196-205.
28. Manahan-Vaughan D., von Haebler D., Winter C., Juckel G., Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008, 18(2):125-134.
29. Miya K., Inoue R., Takata Y., Abe M., Natsume R., Sakimura K., Hongou K., Miyawaki T., Mori H. Serine racemase is predominantly localized in neurons in mouse brain. J. Comp. Neurol. 2008, 510(6):641-654.
30. Morita Y., Ujike H., Tanaka Y., Otani K., Kishimoto M., Morio A., Kotaka T., Okahisa Y., Matsushita M., Morikawa A., Hamase K., Zaitsu K., Kuroda S. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61(10):1200-1203.
31. Nishikawa T. Analysis of free d-serine in mammals and its biological relevance. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879(29):3169-3183.
32. Okabe S., Collin C., Auerbach J.M., Meiri N., Bengzon J., Kennedy M.B., Segal M., McKay R.D. Hippocampal synaptic plasticity in mice overexpressing an embryonic subunit of the NMDA receptor. J. Neurosci. 1998, 18(11):4177-4188.
33. Papouin T., Ladepeche L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L., Pollegioni L., Mothet J.P., Oliet S.H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150(3):633-646.
34. Park J.K., Lee S.J., Kim T.W. Treadmill exercise enhances NMDA receptor expression in schizophrenia mice. J. Exerc. Rehabil. 2014, 10(1):15-21.
35. Puhl M.D., Mintzopoulos D., Jensen J.E., Gillis T.E., Konopaske G.T., Kaufman M.J., Coyle J.T. In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiol. Dis. 2014, 73C:269-274.
36. Puhl M.D., Mintzopoulos D., Jensen J.E., Gillis T.E., Konopaske G.T., Kaufman M.J., Coyle J.T. In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiol. Dis. 2015, 73:269-274.
37. Rabiner E.A. Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. J. Psychopharmacol. 2007, 21(3):253-258.
38. Ripke S., for the Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427.
39. Seeman P., Ko F., Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol. Psychiatry 2005, 10(9):877-883.
40. Sircar R., Soliman K.F. Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. Pharmacol. Biochem. Behav. 2003, 74(4):943-952.
41. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24(4):417-463.
42. Timms A.E., Dorschner M.O., Wechsler J., Choi K.Y., Kirkwood R., Girirajan S., Baker C., Eichler E.E., Korvatska O., Roche K.W., Horwitz M.S., Tsuang D.W. Support for the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013, 70(6):582-590.
43. Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Hansen K.B., Yuan H., Myers S.J., Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010, 62(3):405-496.
44. Wiescholleck V., Manahan-Vaughan D. Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology 2013, 74:48-58.
45. Wong E.H., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(18):7104-7108.
46. Zou H., Zhang C., Xie Q., Zhang M., Shi J., Jin M., Yu L. Low dose MK-801 reduces social investigation in mice. Pharmacol. Biochem. Behav. 2008, 90(4):753-757.